Baxter International Inc. (NYSE: BAX) today announced that it completed production of its first commercial batches of A/H1N1 pandemic vaccine in late July and is discussing plans for distribution with national health authorities, subject to obtaining appropriate authorizations. The company’s A/H1N1 pandemic influenza vaccine is made using Baxter’s proprietary Vero cell culture technology. Baxter plans to deliver initial quantities of the vaccine to national public health authorities that have